Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA048077-09
Application #
2092898
Study Section
Special Emphasis Panel (ZRG2-ET-1 (01))
Project Start
1989-09-01
Project End
2000-01-31
Budget Start
1996-04-09
Budget End
1997-01-31
Support Year
9
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
University of Pittsburgh
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213

  Publications

Yu, W D; Chang, M J; Trump, D L et al. (1997) Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity. Cancer Immunol Immunother 44:316-22
McElwain, M C; Modzelewski, R A; Yu, W D et al. (1997) Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol 18:293-8
Chang, M J; Modzelewski, R A; Russell, D M et al. (1996) Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells. Cancer Res 56:886-91
Grandis, J R; Chang, M J; Yu, W D et al. (1995) Antitumor activity of interleukin-1 alpha and cisplatin in a murine model system. Arch Otolaryngol Head Neck Surg 121:197-200
Modzelewski, R A; Davies, P; Watkins, S C et al. (1994) Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54:336-9
Chang, M J; Yu, W D; Reyno, L M et al. (1994) Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res 54:5380-6
Johnson, C S; Chang, M J; Yu, W D et al. (1993) Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemother Pharmacol 32:339-46
Chang, M J; Pourbohloul, S C; Yu, W D et al. (1992) Differential effect in vitro of tumor necrosis factor-alpha (TNF) on normal and virus-infected erythroid progenitors from Friend virus (FVA)-infected mice. Exp Hematol 20:1271-7
Braunschweiger, P G; Jones, S A; Johnson, C S et al. (1991) Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents. Int J Radiat Biol 60:369-72
Braunschweiger, P G; Jones, S A; Johnson, C S et al. (1991) Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Cancer Res 51:5454-60

Showing the most recent 10 out of 21 publications